Drug Repurposing Market was valued at USD 35.33 Bn in 2024 is expected to grow at a CAGR of 4.9% from 2025 to 2032 and reach USD 51.80 Bn by the end of 2032.
Explore additional details by clicking the link provided: https://www.maximizemarketresearch.com/request-sample/273130/
About the Market
Drug repurposing identifies new therapeutic uses for existing or investigational drugs by leveraging prior clinical and biological data. This strategy accelerates development, reduces costs and trial phases, and enhances accessespecially for neglected diseases. Established supply chains streamline formulation and delivery, while drug combinations and novel mechanisms of action boost efficacy, overcoming early research barriers and fulfilling unmet medical needs.
Global Drug Repurposing Market Segmentation
In 2024, Disease-centric Segment Held the Dominant Position with A Share of Above 42% While Biologics Segment Dominated the Drug Repurposing Market In 2024 and accounted for 23% Of the Global Revenue Share.
For a deeper understanding, click on the link below: https://www.maximizemarketresearch.com/request-sample/273130/
By Type Of Approach
Disease-centric
Target-centric
Drug-centric
By Therapeutic Area
Same Therapeutic Area
Different Therapeutic Area
By Drug Molecules
Biologics
Small Molecule
To dive into the specifics, click the below link: https://www.maximizemarketresearch.com/market-report/drug-repurposing-market/273130/
Drug Repurposing Market Regional Analysis
In 2024, North America held the largest revenue share in the Drug Repurposing Market, contributing approximately 50.2%, followed by Europe as the second-largest region with around 35.5% of the market share. North America and Europe dominate due to robust R&D infrastructure, substantial government and private funding, and streamlined regulatory pathways. Advanced biopharma ecosystems and strong academicindustry collaborations accelerate repurposing initiatives.
Market key players Fueling industry evolution
These companies are leading the Drug Repurposing Market, demonstrating strong financial performance and strategic investments in product development and market expansion:
Pfizer $100.3 billion
Johnson & Johnson $94.9 billion
Roche CHF 68.5 billion (≈ $74.3 billion)
Merck & Co. $59.3 billion
Novartis $52.3 billion
New Related Markets Published by Maximize Market Research.
Drug Device Combination Products Market: The Drug Device Combination Products Market size was valued at USD 118.2 Billion in 2024 and the total Drug Device Combination Products Market size is expected to grow at a CAGR of 8.2% from 2025 to 2032, reaching nearly USD 222.04 Billion by 2032
Drug and Alcohol Screening Market: Drug and Alcohol Screening Market size was valued at USD 7.40 Bn. in 2023 and the total revenue is expected to grow at a CAGR of 17.9% through 2024 to 2030, reaching nearly USD 23.57 Bn.
Drug Delivery Devices Market: The Drug Delivery Devices Market size was valued at USD 279.91 Billion in 2024 and the total Drug Delivery Devices revenue is expected to grow at a CAGR of 7.4% from 2025 to 2032, reaching nearly USD 495.51 Billion.